Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNF26 antisense RNA 1 (RNF26-AS1) is a long noncoding RNA gene transcribed from the antisense strand overlapping the protein-coding RNF26 gene. Its specific biological functions remain largely uncharacterized. Antisense lncRNAs can regulate adjacent genes through several mechanisms, such as mRNA stability modulation, transcriptional interference, or epigenetic regulation. There is currently no evidence that RNF26-AS1 functions as a drug target or that it plays a direct therapeutic or disease-modifying role. No drugs or biomarkers involving RNF26-AS1 are described in the literature[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNF26 antisense RNA 1 (RNF26-AS1).